Chardan analyst Geulah Livshits downgraded Editas Medicine (EDIT) to Neutral from Buy and withdrew the firm’s price target after the company announced a strategic transition to focus entirely on ...
Fintel reports that on May 8, 2023, Credit Suisse maintained coverage of Editas Medicine (NASDAQ:EDIT) with a Neutral recommendation. As of April 24, 2023, the average one-year price target for Editas ...
JPMorgan analyst Tessa Romero kept a Neutral rating with no price target on Prime Medicine (PRME) following a transfer of coverage. The firm says it would consider recommending the shares as the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback